Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD4-positive donor lymphocytes
- Development stage
- Unknown
- Lead developer
- Leiden University Medical Center
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
CD4-positive donor lymphocytes is an investigational cellular immunotherapy being developed by Leiden University Medical Center (LUMC). The therapy consists of purified CD4-positive (helper) T-lymphocytes derived from an allogeneic donor. It is administered as a prophylactic infusion approximately three months after T-cell depleted allogeneic stem cell transplantation in patients with leukemia. The mechanism of action involves donor CD4+ T-cells recognizing minor histocompatibility antigens (MiHA) presented on HLA class II molecules, which are primarily expressed on hematopoietic and malignant cells. This recognition triggers a graft-versus-leukemia (GvL) effect, aiming to prevent disease relapse while minimizing the risk of graft-versus-host disease (GVHD).
- Other names
- CD4+ donor lymphocyte infusionCD4+ DLIpurified CD4-positive helper T-lymphocytes
02
Targets
mHAg-HLA-II (Minor histocompatibility antigen (mHAg) peptides presented by HLA class II molecules)MiHA (Minor histocompatibility antigen)mHag (Non-hematopoietic minor histocompatibility antigen)
Beyond the preview
Go deeper on CD4-positive donor lymphocytes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD4-positive donor lymphocytes.